Efficacy and safety of duloxetine in the treatment of generalized anxiety disorder: A flexible-dose, progressive-titration, placebo-controlled trial

Depression and Anxiety

Volumn 25, Issue 3, 2008, Pages 182-189

  Rynn, Moira ^a,e   Russell, James ^b   Erickson, Janelle ^b   Detke, Michael J ^b,c,d   Ball, Susan ^b,d   Dinkel, Jeff ^b   Rickels, Karl ^a   Raskin, Joel ^b  

^a UNIVERSITY OF PENNSYLVANIA   (United States)

^b ELI LILLY AND COMPANY   (United States)

^c MCLEAN HOSPITAL   (United States)

^d INDIANA UNIVERSITY SCHOOL OF MEDICINE   (United States)

^e NEW YORK STATE PSYCHIATRIC INSTITUTE   (United States)

Author keywords

Adults; Antidepressive agents; Anxiety disorders; Dual reuptake inhibitors; Generalized anxiety disorder; Pharmacotherapy; Serotonin; and norepinephrine; Treatment

Indexed keywords

DULOXETINE; PLACEBO; SEROTONIN NORADRENALIN REUPTAKE INHIBITOR;

ADULT; ARTICLE; CLINICAL GLOBAL IMPRESSION SCALE; CLINICAL TRIAL; CONSTIPATION; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DEMOGRAPHY; DISABILITY; DIZZINESS; DOUBLE BLIND PROCEDURE; DRUG DOSE TITRATION; DRUG EFFICACY; DRUG SAFETY; DRUG WITHDRAWAL; FATIGUE; FEMALE; GENERALIZED ANXIETY DISORDER; HAMILTON ANXIETY SCALE; HOSPITAL ANXIETY AND DEPRESSION SCALE; HUMAN; INSOMNIA; LIBIDO DISORDER; MAJOR CLINICAL STUDY; MALE; MULTICENTER STUDY; NAUSEA; OUTPATIENT CARE; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; SHORT COURSE THERAPY; SOMNOLENCE; STATISTICAL ANALYSIS; TREMOR; XEROSTOMIA;

ADULT; AMBULATORY CARE; ANTIDEPRESSIVE AGENTS; ANXIETY DISORDERS; DIZZINESS; DOSE-RESPONSE RELATIONSHIP, DRUG; DOUBLE-BLIND METHOD; DRUG ADMINISTRATION SCHEDULE; FEMALE; HUMANS; MALE; NAUSEA; PLACEBOS; PSYCHIATRIC STATUS RATING SCALES; SEVERITY OF ILLNESS INDEX; SLEEP DISORDERS; THIOPHENES; TREATMENT OUTCOME;

EID: 41849137610     PISSN: 10914269     EISSN: 15206394     Source Type: Journal    
DOI: 10.1002/da.20271     Document Type: Article

References (29)

1. Baldwin DS, Polkinghorn C. 2005. Evidence-based pharmacotherapy of generalized anxiety disorder. Int J Neuropsychopharmacol 8:293-302.
2. Belzer K, Schneier FR. 2004. Comorbidity of anxiety and depressive disorders: Issues in conceptualization, assessment, and treatment. J Psychiatr Pract 10:296-306.
3. Bymaster FP, Dreshfield-Lamad LJ, Threldkeld PG, Shaw JL, Thompson L, Nelson DL, Hemrick-Leucke SK, Wong DT. 2001. Comparative affinity of duloxetine and venlafaxine for serotonin and norepinephrine transporters in vitro and in vivo, human serotonin receptor subtypes, and other neuronal receptors. Neuropsychopharmacology 25:871-880.
4. Crippa JS, Zuardi AWZ. 2005. Duloxetine in the treatment of panic disorder. Inter J Neuropsychopharmacol 0:1-2.
5. Connor KM, Davidson JRT. 1998. Generalized anxiety disorder: Neurobiological and pharmacotherapeutic perspectives. Biol Psychiatry 44:1286-1294.
6. Detke MJ, Lu Y, Goldstein DJ, McNaniara RK, Demitrack MA. 2002. Duloxetine, 60 mg once daily, for major depressive disorder: A randomized double-blind placebo-controlled trial. J Clin Psychiatry 63:308-315.
7. Doyle AC, Pollack MH. 2003. Establishment of remission criteria for anxiety disorders. J Clin Psychiatry 64:40-45.
8. Goodman WK. 2004. Selecting pharmacotherapy for generalized anxiety disorder. J Clin Psychiatry 65(Suppl 13):8-13.
9. Guy W. 1976a. The clinician global severity and impression scales. In ECDEU assessment manual for psychopharmacology (DHEW Publication No. 76-338). Rockville, MD: NIMH. p 218-222.
10. Guy W. 1976b. The patients' global impression and severity scale. In ECDEU assessment manual for psychopharmacology (DHEW Publication No. 76-338). Rockville, MD: NIMH.
11. Hamilton M. 1959. The assessment of anxiety states by rating. Br J Med Psychol 32:50-55.
12. Hamilton M. 1967. Development of a rating scale for primary depressive illness. Br J Soc Clin Psychol 6:278-296.
13. Kessler RC, Berglund P, Demler O, Jin R, Merikangas KR, Walters EE. 2005a. Lifetime prevalence and age-of-onset distributions of DSM-IV disorders in the National Comorbidity Survey Replication. Arch Gen Psychiatry 62:593-602.
14. Kessler RC, Chiu WT, Demler O, Merikangas KR, Walters EE. 2005b. Prevalence, severity, and comorbidity of 12-month DSM-IV disorders in the National Comorbidity Survey Replication. Arch Gen Psychiatry 62:617-627.
15. Lipsitz J, Kobak K, Feiger A, Sikitch D, Moroz G, Engelhard A. 2004. The Rater Applied Performance Scale: Development and reliability. Psychiatry Res 127:147-155.
16. Pollack MH. 2001. Optimizing pharmacotherapy of generalized anxiety disorder to achieve remission. J Clin Psychiatry 62(Suppl 19):20-25.
17. Rickels K, Downing R, Schweitzer E, Hassman H. 1993. Anti-depressants for the treatment of generalized anxiety disorder: A placebo-controlled comparison of imipramine, trazodone, and diazepam. Arch Gen Psychiatry 50:884-895.
18. Rickels K, Pollack MH, Sheehan DV, Haskins JT. 2000. Efficacy of extended-release venlafaxine in nondepressed outpatients with generalized anxiety disorder. Am J Psychiatry 157:968-974.
19. Rynn MA, Brawman-Mintzer O. 2004. Generalized anxiety disorder: Acute and chronic treatment. CNS Spectr 9:716-723.
20. Schweizer E, Rickels K. 1997. Placebo response in generalized anxiety: Its effect on the outcome of clinical trials. J Clin Psychiatry 58(Suppl 11):30-37.
21. Shear MK, Vander Bilt J, Rucci P, Endicott J, Lydiard B, Otto MW, Pollack MH, Chandler L, Williams J, Ali A, Frank DM. 2001. Reliability and validity of a structured interview guide for the Hamilton Anxiety Rating Scale (SIGH-A). Depress Anxiety 13:166-178.
22. Sheehan DV. 1983. The anxiety disease. New York: Scribner and Sons.
23. Sheehan DV, Lecrubier Y, Sheehan KH, Amorim P, Janavas J, Weiller E, Hergueta T, Baker R, Dunbar GC. 1998. The MINI International Neuropsychiatric Interview for DSM. J Clin Psychiatry 59(Suppl 20):34-57.
24. Stein MB. 2004. Public health perspectives on generalized anxiety disorder. J Clin Psychiatry 65(Suppl 13):3-7.
25. Troelsen KB, Nielsen EO, Mirza NR. 2005. Chronic treatment with duloxetine is necessary for an anxiolytic-like response in the mouse zero maze: The role of the serotonin transporter. Psychopharmacology 181:741-750.
26. Vasile RG, Bruce SE, Goisman RM, Pagano M, Keller MB. 2005. Results of a naturalistic longitudinal study of benzodiazepine and SSRI use in the treatment of generalized anxiety and social phobia. Depress Anxiety 22:59-67.
27. Wittchen HU. 2002. Generalized anxiety disorder: prevalence, burden, and cost to society. Depress Anxiety 16:162-171.
28. World Medical Association. 2000. Declaration of Helsinki: Ethical principles for medical research involving human subjects. Available from http://www.wma.net/e/policy/17-c_e.html.
29. Zigmond AS, Snaith RP. 1983. The Hospital Anxiety and Depression Scale. Acta Psychiatric Scandinavia 67:361-370.